Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sanegene Bio is a clinical-stage biopharmaceutical company specializing in the development of innovative RNA interference (RNAi) therapeutics. The company utilizes its proprietary LEAD (Liver-targeting Efficient delivery and Accelerated Development) platform to create a diverse pipeline of siRNA drugs targeting chronic diseases with high unmet medical needs. Their primary focus areas include cardiovascular, metabolic, and hematological disorders. Sanegene Bio aims to leverage its expertise in oligonucleotide chemistry and delivery technology to provide long-acting and effective treatments. The company is headquartered in Suzhou, China, with additional R&D operations in the United States. Its lead program, SNG1005, is currently in clinical development for the treatment of dyslipidemia.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Suzhou Sanegene Bio.